0.6728

1.07% -0.0073

Pre-market: .69 0.0172 +2.56%

Allarity Therapeutics Inc (ALLR)

Overview News Price History Financials Discussions Forecast Stock Split

Allarity Therapeutics Inc stock is currently priced at $0.6728, with a 24-hour trading volume of 2.73M. It has seen a -1.07% decreased in the last 24 hours and a -59.95% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $0.6877 pivot point. If it approaches the $0.6354 support level, significant changes may occur.

Previous Close:

$0.6801

Open:

$0.6742

24h Volume:

2.73M

Market Cap:

$1.74M

Revenue:

Net Income/Loss:

$-11.90M

P/E Ratio:

-0.0028

EPS:

-239.88

Net Cash Flow:

$-12.75M

1W Performance:

-10.77%

1M Performance:

-59.95%

6M Performance:

+37.12%

1Y Performance:

+90.33%

1D Range:

$0.6622

$0.7185

52W Range:

$0.1501

$13.49

Allarity Therapeutics Inc Stock (ALLR) Company Profile

Name

Allarity Therapeutics Inc

Sector

Healthcare (1211)

Industry

Biotechnology (697)

Phone

401 426 4664

Address

210 Broadway, Suite 201, Cambridge

Employee

Twitter

Next Earnings Date

Latest SEC Filings

ALLR's Discussions on Twitter

Allarity Therapeutics Inc Stock (ALLR) Latest News

ALLR Stock Earnings: Allarity Therapeutics Reported Results for Q1 2024 - MSN

MSN

Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from ... - GlobeNewswire

GlobeNewswire

Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances

GlobeNewswire Inc.

Wall Street analysts' outlook for Allarity Therapeutics Inc (ALLR) – Sete News - SETE News

SETE News

Allarity Therapeutics Restructures Capital and Reduces Debt - TipRanks.com - TipRanks

TipRanks

All You Need to Know About Allarity Therapeutics, Inc. (ALLR) Rating Upgrade to Buy - Zacks Investment Research

Zacks Investment Research

Allarity Therapeutics Inc Stock (ALLR) Financials Data

Allarity Therapeutics Inc (ALLR) Net Income 2024

ALLR net income (TTM) was -$11.90 million for the quarter ending December 31, 2023, a +25.89% increase year-over-year.

Allarity Therapeutics Inc (ALLR) Cash Flow 2024

ALLR recorded a free cash flow (TTM) of -$12.74 million for the quarter ending December 31, 2023, a +24.21% increase year-over-year.

Allarity Therapeutics Inc (ALLR) Earnings per Share 2024

ALLR earnings per share (TTM) was -$206.01 for the quarter ending December 31, 2023, a +94.07% growth year-over-year.

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.